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PURPOSE. Cystatin C, a potent cysteine proteinase inhibitor, is abundantly secreted by the RPE
and may contribute to regulating protein turnover in the Bruch’s membrane (BrM). A cystatin
C variant associated with increased risk of developing AMD and Alzheimer’s disease (AD)
presents reduced secretion levels from RPE. The purpose of this study was to analyze the
effects of age and the accumulation of advanced glycation end-products (AGEs) on the
expression and secretion of cystatin C by the RPE.
METHODS. Confluent monolayers of human fetal RPE (hfRPE) cells were cultured using an in
vitro model mimicking extracellular AGE accumulation. Cystatin C expression, secretion, and
its polarity were analyzed following culture on AGE-containing BrM mimics (AGEd versus non-
AGEd). Monolayer barrier properties were assessed by transepithelial resistance measure-
ments. The relative level of cystatin C protein expression in human RPE in situ was assessed
immunohistochemically in relation to age.
RESULTS. Advanced glycation end product–exposed RPE monolayers presented significantly
decreased cystatin C expression and secretion. Basolateral secretion was fully established by
week 8 in non-AGEd conditions. In AGEd cultures, polarity of secretion was impaired despite
maintenance of physiological barrier properties of the monolayer. In the macula region of
RPE/choroid segments from human eyes, the level of cystatin C protein was reduced with
increasing donor age.
CONCLUSIONS. Exposure to AGEs reduces expression of cystatin C and affects its normal
secretion in cultured RPE. Age-related changes of cystatin C in the RPE from the posterior
pole may compromise its extracellular functions, potentially contributing to AMD
pathogenesis.
Keywords: cystatin C, secretion, aging, retinal pigment epithelium
The RPE forms a highly polarized monolayer essential forcontrolling spatial and temporal localization of extracellular
proteins on its apical (neuroretinal) and basolateral (Bruch’s
membrane [BrM]/choroidal) sides.1 The majority of RPE cells
maintain a nonproliferative state2,3 and a relatively long life-
span, as does the RPE underlying support matrix, the BrM. This
longevity makes them susceptible to a myriad of age-related
changes that can affect essential cellular processes. Obtaining a
greater understanding of the aging process as a predisposing
factor has become a key area of interest in the study of AMD, a
disease associated with significant changes in the secreted
proteome of the RPE.4
Cystatin C is among the most abundantly expressed proteins
of the RPE (within the top 2% of all expressed genes in both
human and mouse studies).5–8 The precursor of this cysteine
proteinase inhibitor contains an N-terminal signal peptide of 26
amino acids that is essential for targeting it to the endoplasmic
reticulum (ER)/Golgi classical secretory pathway.9,10 A poly-
morphism in the signal sequence (Ala25Thr due to a G73A
substitution) results in an alternate homologue, variant B,
homozygosity for which was reported to be correlated with an
increased risk of exudative AMD development.11 Notably, the
same autosomal recessive allele was extensively documented in
relation to increased risk for developing Alzheimer’s disease in
the Caucasian population.12,13 The single amino acid change
leads to mistrafficking of the protein away from the ER to the
mitochondria,14 likely owing to reduced hydrophobicity of the
signal sequence,15 and subsequently results in significantly
decreased secretion compared with the wild type.14 The role of
cystatin C in the RPE has not yet been fully characterized, yet its
high expression and secretion, coupled with its specific
inhibitory properties on cysteine proteinases (cathepsins B,
H, L, and S)16,17 suggest a role in matrix remodeling and
turnover, processes often prone to malfunction during AMD
progression.
Protein modification described by Maillard reactions is a
common phenomenon during the aging process, resulting in
advanced glycation end-product (AGE) formation.18 These
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adducts are the result of reactions between e-amino groups and
glucose, a-oxaloaldehydes, and lipid peroxidation products.18
Advanced glycation end products accumulate on long-lived
structural proteins such as collagen,19 where, by altering their
structure and function, they can contribute to the develop-
ment of age-related disease.20 Advanced glycation end-product
accumulation occurs in the BrM in the eyes of aging
patients21–23 and is associated with AMD development.24–27
Exposure to AGEs has been shown to alter the gene expression
profile of cultured RPE cells, subsequently leading to altered
functional capacity.23,28,29
In the present study, we analyzed the effects of the
accumulation of AGEs and of increasing age on the expression
and polarized secretion of cystatin C. We showed that
following exposure of RPE cells to AGEs, both expression
and secretion of cystatin C were reduced, while the polarity of
its secretion was impaired. The results were corroborated by
the reduction of the relative level of cystatin C protein
expression with increasing age in the macula region in situ.
We propose that the age-related decline of extracellular
cystatin C plays a role in the imbalance of proteolytic activities
on the basal side of RPE, which may contribute to the
mechanisms underlying AMD pathogenesis.
METHODS
Cell Culture
Human fetal RPE (hfRPE) cells were extracted and cultured as
previously described.30 Human fetal RPE cells obtained from
two separate donors (donors 1 and 2) were used in the
majority of experiments. In some cases, cells obtained from a
third donor (donor 3) were required. Culture media for hfRPE
cells (MEM, a modification) and media supplements were
obtained from Sigma-Aldrich (Poole, UK), with N2 supplement
(Life Technologies, Paisley, UK) replacing N1 supplement. Cells
were maintained in 25-cm2 flasks at 378C in 5% CO2 from time
of receipt (passage 0) to no more than passage 2. Fresh media
were added to flasks three times per week, and monolayers
were analyzed on a weekly basis to ensure cells retained their
‘‘cobblestone’’ morphology and pigmentation.
AGE Modification of Extracellular Matrix (ECM)
and Seeding of hfRPE Cells
All hfRPE experiments were carried out in either standard 24-
well cell culture plates, or in 12-well Transwell plates (12-mm
diameter polyester inserts, 0.4-lm pores; Sigma-Aldrich). Wells
were coated overnight with human placental ECM (BD
Biosciences, Oxford, UK) to attain a final concentration of 10
lg/cm2. To induce an accumulation of AGEs within the ECM
(from here on referred to as AGEd ECM), wells were then
incubated with 100-mM glycolaldehyde (Sigma-Aldrich) at 378C
for 4 hours, followed by thorough washing with PBS.
Neutralization of remaining aldehyde groups was achieved by
incubating ECM with 50 mM sodium borohydride (Sigma-
Aldrich), followed by thorough washing with PBS. Untreated
(non-AGEd) wells were treated the same, with the exception of
PBS being substituted for glycolaldehyde. To confirm the
presence of AGEs in our experimental model, ECM was also
seeded into black 96-well plates and treated as described
above. Maillard-type fluorescence (excitation 370 nm, emission
440 nm) was then measured using a fluorescent plate reader
(BMG Labtech, Aylesbury, UK).
Human fetal RPE cells were trypsinized, and approximately
1.5 3 105 cells were seeded per Transwell or 2.5 3 105 per
standard well. Although all hfRPE monolayers used were
expected to be highly polarized, this could only be confirmed
experimentally when cultured in Transwells. Therefore, to
distinguish between these two culture methods, we refer to
Transwell monolayers as ‘‘fully polarized’’ throughout the study.
Cells were cultured in media containing 15% fetal calf serum
(FCS) overnight and subsequently cultured in standard 5%
growth media for the remainder of the experiments (up to 10
weeks). Most experiments were carried out on cells from donors
1 and 2, and in a few cases, donor 3 (stated in the figure legends).
For each donor, at least three separate replicate wells were used
for each experimental condition. When comparisons of cell
numbers were required between treatment groups, quantifica-
tion was carried out using an MTT assay kit (Life Technologies),
with relative data expressed as optical density (OD) units.
Determination of Transepithelial Resistance (TER)
The TER across hfRPE monolayers in Transwells was measured
with a volt-ohm meter within 10 minutes of removing the
culture plate from the incubator. All wells were measured three
times and averaged. The TER of a blank well was used as a
baseline value and subtracted from all experimental measure-
ments, and the final TER was calculated by multiplying by the
effective growth area of the Transwell (1.12 cm2).
Western Immunoblotting
At least two separate conditioned media samples were
collected and analyzed for each experimental condition, 48
to 72 hours after change of media. When using Transwells, the
volume of the upper chamber was normalized to match that of
the lower chamber using serum-free media. Unconditioned,
full-serum growth media were previously analyzed by Western
blot and produced no bands following probing with any of the
antibodies used in this study (this ensured that all analyzed
proteins were present in conditioned media as a result of
hfRPE secretion). For conditioned media samples, normaliza-
tion of protein content was carried out before analysis, as the
effects of AGEs on secretion of potential loading controls was
unknown. Protein content was determined using a Qubit
fluorometer (Life Technologies), and protein was loaded
equally by mass. Cell lysates were collected following addition
of lysis/sample buffer14 to wells.
Samples were resolved by SDS-PAGE, alongside a molecular
weight marker (Thermo Scientific, Northumberland, UK), and
Western blot analysis was then carried out as previously
described.10 An aliquot of the same random sample of
conditioned media was loaded onto every gel as an internal
control to normalize for differences between blots. Primary
antibodies used were anti-cystatin C (Millipore, Watford, UK)
diluted 1:2000, anti-pigment epithelium–derived factor (anti-
PEDF) (Millipore) diluted 1:1000, and anti a-tubulin (Sigma-
Aldrich) used at 1:10,000 dilution. Secondary antibodies used
were horseradish peroxidase (HRP)-conjugated anti-rabbit and
anti-mouse (Sigma-Aldrich). Membranes were prepared for
chemiluminescence measurements using ECL Prime Western
Blotting Detection Reagent (GE Healthcare, Little Chalfont,
UK) and imaged using a ChemiDoc (Bio-Rad, Hertfordshire,
UK). Densitometry of bands was carried out using ImageLab
software (Bio-Rad). Final optical density values were calculated
by normalizing all readings to that of the internal control on
each blot (given an arbitrary value of 1), and in the case of cell
lysates, by also normalizing to the loading control (a-tubulin).
ELISA for Cystatin C
Conditioned media samples were collected from hfRPE
monolayers grown in standard 24-well culture plates at varying
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time points after replacement (24, 48, and 72 hours). Following
a 1:4 dilution, cystatin C concentration was determined using a
Quantikine human cystatin C ELISA Kit (R&D Systems,
Abingdon, UK), following the manufacturer’s protocol. Values
obtained (nanograms per milliliter) were multiplied by four
(dilution factor) to obtain final concentrations.
Real-Time Quantitative PCR (qPCR)
RNA was isolated from cells using the RNeasy Plus Mini-Kit
(Qiagen, West Sussex, UK). Complementary DNA was synthe-
sized from 0.3 lg RNA using an RT2 First Strand Synthesis Kit
(Qiagen). Quantitative PCR was performed using the MESA
BLUE qPCR Mastermix Plus Kit for SYBR assay (Low ROX;
Eurogentec, Southampton, UK) using a modified version of a
previous protocol.31 The primer set used for cystatin C was 50-
GCCGAACCACGTGTACCAAG-3 0 and 5 0-AGGTGGATTTCGA
CAAGGTCATT-30. Final values are expressed relative to a
calibrator sample assigned an arbitrary value of 1 and
normalized to glyceraldehyde 3-phosphate dehydrogenase
(GAPDH; primer set: 50-AACAGCCTCAAGATCATCAG-30 and
50-TGAGTCCTTCCACGATACC-30) using the efficiency-correct-
ed DDCt method. Reactions were run on a Stratagene
MX3000P qPCR System (Stratagene, La Jolla, CA), and three
technical replicates were used for each cDNA sample. The
specificity of amplification reactions was confirmed by melt-
curve analysis and agarose gel electrophoresis.
Donor Tissue Preparation for
Immunohistochemistry
The local research ethics committee granted ethical approval
for the study, and the research adhered to the tenets of the
Declaration of Helsinki. Human eyes were obtained from the
local eye bank (Royal Liverpool University Hospital, Liverpool,
UK). Thirty-five human eyes, each obtained from a different
donor with no history of ocular disease and with an age range
of 17 to 95 years were used. Eyes were identified only by their
specimen number throughout the study, ensuring that they
remained anonymized and age masked. Unmasking was carried
out following data collection, to allow for final analysis. Tissue
sections were prepared as previously described.32
Immunohistochemical Analysis
Sections were processed as previously described,32 with the
addition of a protein block with 20% goat serum (Dako, Ely,
UK). Incubation with 5 lg/mL of rabbit anti-cystatin C
(Millipore) was then carried out. Negative control sections
had primary antibody omitted (incubated in 1% goat serum).
Sections were then incubated with Dako EnVision anti-rabbit
labeled polymer-HRP conjugate. Visualization was achieved
using Dako 3-amino-9-ethylcarbazole substrate. Sections were
then mounted in Vectormount AQ aqueous mounting media
(Vector Laboratories, Peterborough, UK). In order to ensure
that variability of staining was reduced, the conditions for the
immunohistochemical staining were first optimized and
repeated on a subset of specimens, which were then included
and compared in each run alongside all specimens.
The RPE cells were imaged using a light microscope with a
digital camera, as previously described.32 Images were taken of
the posterior pole segment (corresponding to the macula) and
compared with the peripheral RPE of each specimen. Analysis
was carried out using ImageJ software (National Institutes of
Health, Bethesda, MD). Images were inverted (white ¼
grayscale value of 0, and black ¼ grayscale value of 255), and
the mean gray value for each area was measured. For each
image, the average of the three mean gray-value measurements
was taken, and the mean gray value of the negative control
most closely resembling the background conditions of the
sample was deducted. Posterior pole and periphery segments
were analyzed separately. For this study, posterior RPE cells
were defined as those that lay temporal to the optic nerve and
within the area of the retinal vascular arcades; peripheral RPE
cells were defined as those that lay anterior to the equator of
the globe. Periphery measurements of opposite sides of each
globe were averaged.
Statistical Analysis
All statistical analysis was carried out using SPSS for Windows
(Version 20; IBM, Portsmouth, UK). A P value of less than 0.05
was considered to be statistically significant.
RESULTS
AGE Accumulation on the Basal ECM Impacts on
Cystatin C Expression
To determine the effects of aging on the expression and
secretion of cystatin C in the RPE, an in vitro system was used
with the ability to mimic one of the most common biochemical
changes associated with aging and age-related disease: the
accumulation of AGEs on long-lived protein structures.
Human fetal RPE cells were cultured for 2 weeks on either
untreated ECM (non-AGEd), or ECM pretreated to induce the
accumulation of AGEs (AGEd). Whole cell lysates from these
cells were then used to analyze cystatin C expression by
Western blot and qPCR (Fig. 1). This experiment revealed
FIGURE 1. Cystatin C expression in hfRPE cells on AGEd ECM. (A)
Representative Western blot shows cystatin C and a-tubulin expression
of hfRPE cells (1 donor displayed) from three separate untreated-(non-
AGEd) and three separate AGE-treated (AGEd) wells. Graph shows the
average normalized cystatin C expression (arbitrary units)þ SEM for all
samples tested (donors 1 and 2); for each condition, n¼ 6. (B) Cystatin
C mRNA expression in hfRPE cells as determined by qPCR analysis.
Graph shows average normalized expression (arbitrary units)þ SEM for
all samples tested (donors 1 and 2); for each condition, n ¼ 6. (C)
Advanced glycation end-product–specific fluorescence on both un-
treated and treated ECM samples; for each condition, n ¼ 4.
Independent t-test; *P < 0.05, **P < 0.01. NA, non AGEd; A, AGEd.
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cystatin C expression was decreased as a result of AGE-
accumulation on the basal substratal ECM on which RPE cells
were grown. A similar decrease was observed at both the
protein (Fig. 1A) and RNA levels (Fig. 1B). Expression levels of
genes used for normalization (a-tubulin for protein analysis and
GAPDH for mRNA analysis) were not significantly affected by
AGE accumulation (values used to normalize cystatin C data,
not shown separately). An increase in AGE-specific fluores-
cence on ECM following glycolaldehyde treatment confirmed
the presence of AGEs in our experimental model (Fig. 1C).
AGEd Basal ECM Decreases Cystatin C Secretion by
RPE
The next step was to determine if the observed reduction in
cystatin C protein expression resulted in a corresponding
decrease in cystatin C secretion from the RPE monolayer.
Conditioned media collected from the cells were analyzed by
immunoblotting for cystatin C alongside PEDF as a control,
known to also be secreted at high levels from hfRPE cells.30,33
Secretion of cystatin C was significantly decreased following
culture on AGEd ECM for 2 weeks compared with non-AGEd
(Fig. 2A), while PEDF was secreted at similar levels from cells
cultured on both AGEd and non-AGEd ECM. ELISA analysis
revealed that total secretion of cystatin C from hfRPE
monolayers averaged approximately 57 ng/mL/24 h (Fig. 2B).
Secretion levels were significantly reduced following culture
on AGEd ECM at both the 48- and 72-hour time points.
Polarized Secretion of Cystatin C From hfRPE Cells
on Non-AGEd and AGEd ECM
To analyze polarized secretion of cystatin C, as well as potential
effects on this pattern caused by the presence of AGEs, hfRPE
cells were cultured on non-AGEd and AGEd ECM in Transwell
inserts (fully polarized). This allowed cells to establish distinct
apical and basolateral secretion patterns. Cells were monitored
over an extended period of time (up to 10 weeks). Conditioned
media were collected from upper and lower chambers of
Transwells at different points throughout the 10-week time
course. After 4 weeks, non-AGEd monolayers reached a TER of
approximately 250Xcm2 and showed equal secretion of
cystatin C into both the upper (apical) and lower (basal)
chambers (Fig. 3A). Pigment epithelium–derived factor secre-
tion was also nonpolarized at this stage. However, AGEd
monolayers had not attained the minimum TER of 200Xcm2,
so they were not analyzed for polarized secretion at this stage.
The AGEd monolayers reached the threshold TER of
200Xcm2 after 8 to 0 weeks post seeding, so direct
comparisons could now be made of non-AGEd and AGEd
polarized secretion. At this stage, cystatin C was secreted
significantly more abundantly into the basal chamber of non-
AGEd monolayers, whereas PEDF was secreted preferentially
into the apical chamber in line with previous reports30,33 (Fig.
3B). In AGEd monolayers, however, secretory polarity of both
cystatin C and PEDF was not present, with both proteins being
secreted equally into apical and basal chambers (Fig. 3C).
FIGURE 2. Cystatin C secretion from hfRPE monolayers cultured on AGEd ECM. (A) Secreted cystatin C and PEDF levels in hfRPE conditioned media
(one donor displayed) from three separate untreated- (non-AGEd) and three separate AGE-treated (AGEd) wells. All blots are representative of
observed secretion patterns. Graphs show average normalized cystatin C and PEDF secretion (arbitrary units)þ SEM for all samples tested (donors 1
and 2); for each condition, n¼12. (B) Concentration of cystatin C over time in hfRPE conditioned media from three separate untreated- (non-AGEd)
and three separate AGE-treated (AGEd) wells (determined by ELISA analysis). Concentration is displayed as nanograms per milliliter 6 SEM for all
samples tested (donor 3); for each condition, at each time point, n ¼ 3. Independent t-test, *P < 0.05. NS, not significant.
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Morphological and physiological (TER) characteristics of
the hfRPE were monitored to determine AGE-related changes.
In the majority of cases, hfRPE cells were able to form typical
monolayers on both non-AGEd and AGEd ECM consisting of a
tightly packed ‘‘cobblestone’’ arrangement of pigmented cells
(Fig. 3D). In a small number of cases, cells seeded onto AGEd
ECM initially adhered less efficiently, presenting holes in the
monolayer within the first week. These holes usually closed
within a few days, resulting in a monolayer similar to those
produced on non-AGEd ECM (monolayers in which holes
remained beyond 1 week post seeding were not used for any
subsequent polarized secretion analysis). No differences in cell
number were observed between non-AGEd and AGEd cultures
(Fig. 3E) following 2 weeks of culture (the point at which cell
monolayers have reached complete confluence and attained a
cobblestone pattern).
FIGURE 3. Polarized secretion of cystatin C by fully polarized hfRPE monolayers and effects of the presence of AGEs. Secreted cystatin C and PEDF
levels in conditioned media collected from the upper (U) and lower (L) chamber of three separate hfRPE monolayers following (A) 4 weeks of
culture in non-AGEd wells, (B) 8 to 10 weeks culture in non-AGEd wells, or (C) 8 to 10 weeks culture in AGEd wells. All blots show results from
three separate wells (one donor displayed) and are representative of observed secretion patterns from all samples tested. Graphs show average
normalized cystatin C and PEDF secretion (arbitrary units)þ SEM for all samples tested (donors 1 and 2); for each condition, n¼12 (paired t-test, *P
< 0.05, **P < 0.01). (D) Images show the typical morphology of hfRPE cells grown for 10 weeks on either untreated- (non-AGEd) or AGE-treated
(AGEd) Transwells. (E) Comparison of cell number of hfRPE monolayers (non-AGEd versus AGEd) 2 weeks after seeding. Measurements expressed
as OD units (MTT assay)þ SEM for all samples tested (donor 3); for each condition, n¼ 3. (F) Transepithelial resistance measurements across hfRPE
monolayers over 10 weeks. Graphs show measurements 6 SEM from both donors studied after culture on untreated- (non-AGEd) or AGE-treated
(AGEd) Transwells; for each condition, n¼ 3. Independent t-test, *P < 0.05, **P < 0.01, ***P < 0.0001. NS, not significant.
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A sharp and constant increase in TER was observed in non-
AGEd monolayers (Fig. 3F), typically reaching approximately
200 to 250Xcm2 within 28 days as previously reported.30,33
Transepithelial resistance increased at a much slower rate for
AGEd monolayers, only reaching 200Xcm2 at around 8 (donor
2) to 10 weeks (donor 1) (Fig. 3F). The consistently increasing
TER readings taken for all conditions indicate the presence of a
functional, intact monolayer. All cultures analyzed maintained a
minimum TER of 200Xcm2 at the final point of analysis.
Cystatin C Relative Protein Level Decreases With
Age in the RPE Underlying the Macula Region
To analyze the relationship between cystatin C expression/
accumulation and age in situ, RPE-containing sections derived
from the eyes of 35 human donors were tested for cystatin C
immunoreactivity. The protein was present in all samples
tested, with varying grades of intensity dependent upon
anatomic location (Fig. 4). Intense staining was observed more
frequently in posterior RPE segments (location of macula) than
in the periphery (Fig. 4A). Analysis of staining intensity in
relation to age revealed a negative correlation between cystatin
C level and increasing age in the posterior (macula) RPE
segment, but not in the peripheral segment (Figs. 4B, 4C).
DISCUSSION
We demonstrated a marked decrease in cystatin C expression
in hfRPE cells cultured on AGEd ECM. This was apparent at the
transcriptional level, leading to decreased protein expression,
and ultimately, reduced secretion. Furthermore, the physiolog-
ically relevant basal polarity of its secretion was lost following
prolonged exposure of cells to AGEs. Previously, the associa-
tion between cystatin C and AMD risk was attributed to the
malfunction in intracellular targeting, and subsequent de-
creased secretion of the variant B homologue.14 Here, we
demonstrated that a physiological change associated with the
aging process can also affect secretion of wild-type cystatin C.
The in vitro model used in our study was adapted from
published protocols23,28,29,34 and utilized the previously
documented accumulation of AGEs on long-lived protein
structures; in this case the substratal ECM on which cells
were cultured. A necessary adaptation was in the use of a
slightly different ECM in order to provide optimal growth
conditions for primary hfRPE cells, which were used to ensure
confluent monolayers with physiological characteristics of
native human RPE.30 The components of the ECM used
(predominantly collagen IV and laminin) were however almost
identical to ECM mimics used in other RPE studies23,28,29 and
provided both an accurate representation of the BrM and a
suitable substrate for glycation reactions.34 Human fetal RPE
cells formed consistent and robust monolayers displaying the
characteristic cobblestone morphology and maintained high
levels of pigmentation. The use of primary hfRPE cells, as
opposed to transformed cell lines, contributed to a physiology
similar to that of native RPE,30,33 resulting in a suitable model
for analyzing secretion/polarity.
The present study also ascertained for the first time that in
situ the abundance of wild-type cystatin C is reduced in the
macula region of the RPE/choroid as a result of increasing age.
Varying demands placed on RPE cells in different regions of the
retina can result in altered gene expression profiles,35
particularly for genes associated with the ECM. It is conceiv-
FIGURE 4. Cystatin C protein expression/accumulation in the RPE in situ. (A) Grading of cystatin C immunoreactivity in sections from posterior and
peripheral RPE segments (positive staining displayed in grades of increasing intensity fromþ toþþþ; -ve indicates primary antibody omitted). (B, C)
Relationship between cystatin C protein expression/accumulation with age. Cystatin C protein level was plotted against the age of each individual
donor, in both posterior (B) and peripheral (C) RPE segments. The line of regression was significant for posterior samples (P < 0.05, R2¼0.1204, n
¼ 35), but not peripheral (R2 ¼ 0.0002, n ¼ 35).
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able that cystatin C expression also varies depending on
topographic location, as evidenced in the present study, where
relative protein levels were higher in the macula across all age
groups compared with peripheral regions. An age-related
decrease in cystatin C in such regions of high demand could
therefore modify the local proteolytic balance. Furthermore,
the decrease would be greatly accelerated in the variant B
expression scenario, thus explaining the increased risk posed
by the respective allele for AMD pathogenesis. Notably, the
reduced level and/or secretion of cystatin C, whether age-
related or consequential to variant B expression, was suggested
as a molecular factor responsible for increased neuronal
vulnerability and risk of neurodegenerative diseases, including
Alzheimer’s disease.13,36–39
Considering its known enzyme targets, it is likely that
cystatin C is involved in proteolytic events that regulate either
maintenance of the BrM or cell-signaling processes on the
basolateral side of RPE. Reduced protein level in this region as a
result of decreased secretion could contribute to AMD-
associated changes, such as disruption in the stability and
function of the BrM,40–42 and increased permeability of RPE.43,44
There is also evidence that cystatin C can interact with
complement component 4,45 and by doing so, may inhibit the
complement cascade. It is therefore possible that reduced levels
of cystatin C secretion could also contribute to the increased
complement activity often associated with AMD pathogenesis.46
Advanced glycation end product–induced gene expression
changes in the RPE were previously documented both at the
transcriptional23,29 and protein levels,28 yet how AGEs alter
cystatin C expression remains to be determined. The cystatin C
promoter shares many similarities to those of housekeeping
genes, suggesting constitutive expression47; however, certain
transcription factors, such as interferon regulatory factor 8 can
bind to the promoter and regulate its activity.48 Transcriptional
regulation can also be achieved following treatment with
dexamethasone49 and TGFb.50 Cystatin C is ubiquitously
expressed in human tissues, yet its abundance can vary greatly,
even among similar cell types.51 This suggests constitutive
expression, subject to cell-specific regulation via particular
transcription factors.
Multiple mechanisms exist by which AGEs can alter gene
expression. The direct mechanism is via activation of the
receptor for advanced glycation end-products (RAGE). Retinal
epithelial cells express RAGE, and its activation can lead to the
alteration of cellular processes such as protein secretion.52
RAGE can modulate a multitude of downstream pathways
including mitogen-activated protein (MAP) kinase signaling via
p21 (ras),53 cdc42 and Rac-1,54 extracellular signal-related
kinase, c-jun N-terminal kinase, and p38.55 RAGE can also
increase nuclear factor kappa B (NF-jB) transcriptional
activity.56 Alternatively, AGEs can affect gene expression via
indirect mechanisms. These can include an increase in
oxidative stress associated with AGE accumulation,57–59 and
the subsequent alteration of multiple cellular functions.
Our results suggest that the gradual exposure of RPE cells to
AGEs may impair their ability to maintain a highly polarized
state and secretion program, which in turn could, in time,
affect the overall transport and, potentially, barrier function of
the monolayer. This is underscored by the alteration in the
directional secretion of not just cystatin C but also PEDF,
indicating a wider effect on the cells. Indeed, it was
demonstrated that attainment of a fully polarized conformation
in culture is enough to augment overall protein secretion by
hfRPE,60 highlighting the importance of this state for correct
functional secretion patterns. Furthermore, in a study compar-
ing the cell line ARPE19 (suggested by the authors to more
closely mimic an aged phenotype) to hfRPE, a decrease in total
VEGF secretion was observed, and also alterations in its
polarized secretion were noted.61 These findings pointed out
the potential of the aging process to alter the polarized state of
cells. In alveolar type II cells, varying components of the
substratal ECM can affect intracellular organization, cell
polarity, and TER measurements.62 Advanced glycation end
product–induced changes in the BrM could have similar
consequences on RPE cells. ARPE19 cells cultured on an
AGE-treated BrM mimic for 4 weeks displayed marked
ultrastructural differences to those cultured on untreated
ECM.23 Perhaps the most relevant of these changes, in terms
of maintained barrier function, was in the apparent reduction
in tight-junction formation in AGE-treated cells. Studies in
retinal endothelial cells demonstrated that short-term exposure
to AGEs can increase permeability across the monolayer,
possibly by affecting tight junctions.63 A similar short-term
study carried out in ARPE19 cells was also able to show an
AGE-dependent decrease in the barrier function of the
monolayer, resulting in decreased TER measurements.64 Our
study represents the first analysis of the long-term effects of
AGEs on well-polarized RPE function, applied to a specific
gene-expression product.
The ability to fully replicate the physiological process of AGE
accumulation in culture has limitations. It is not possible to
gradually bring AGEs into an ECM already supporting live cells, as
occurs in vivo. This limitation is, however, partly countered by
the deposition of new non-AGEd ECM in vitro4,65 during the
formation of fully confluent monolayers, potentially modulating
AGE exposure in culture conditions. In situ, AGE accumulation
increases with age, resulting in a long-term insult that would
likely affect the ability of RPE to retain a polarized state over time,
and to maintain a functional, impermeable barrier to diffusion.
We conclude that a common pathological change associated
with the aging process, the accumulation of AGEs, can alter
both the expression of cystatin C, and the polarity of its
secretion. It is possible that each of these phenomena is the
result of different AGE-induced molecular changes, which may,
or may not, occur simultaneously in situ. It is clear, however,
that even alone, each of these changes can lead to the same
scenario, a significant decrease in cystatin C protein level at its
sites of action. Coupled with the previously established
knowledge regarding decreased secretion of the AMD-associ-
ated variant B,14 these findings are consistent with the
involvement of cystatin C in AMD pathophysiology. The
observed reduction in the extracellular cystatin C protein level
is likely to contribute to reduced control over proteolytic
homeostasis in the retina/choroid, which in turn may
contribute to the well-documented biological changes that
occur with age at this site.66 The potential broader effects
exerted by AGEs on RPE polarity and barrier function are
another important finding. Such AGE-induced changes have the
potential to alter the localization of a multitude of factors and
may contribute to disease pathogenesis in a similar way to
cystatin C mis-localization.
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